新型钾通道开放剂XEN1101治疗成人局灶性癫痫的疗效与安全性:一项2b期随机临床试验
这项2b期随机双盲安慰剂对照平行组剂量探索辅助治疗试验纳入325例成人局灶性起源癫痫患者,按2:1:1:2随机接受XEN1101 25、20、10 mg或安慰剂每日一次治疗8周。结果显示XEN1101呈稳健剂量依赖性减少癫痫发作,25 mg组每月局灶性起源癫痫频率中位降低52.8%(P<.001 vs 安慰剂),20 mg组降低46.4%(P<.001),10 mg组降低33.2%(P=.04),安慰剂组降低18.2%。XEN1101总体耐受良好,无导致死亡的TEAE。
要点
- XEN1101 25 mg组每月FOS频率中位降低52.8%,安慰剂组降低18.2%(P<.001)。
- XEN1101 20 mg组中位降低46.4%(P<.001),10 mg组降低33.2%(P=.04 vs 安慰剂)。
- XEN1101总体耐受良好,TEAE与常用ASM相似,无导致死亡的TEAE。
核心结论
- 该临床试验的疗效和安全性结果支持XEN1101用于治疗局灶性起源癫痫的进一步临床开发。
研究设计与样本
- 2b期随机双盲安慰剂对照平行组剂量探索辅助治疗试验,2019年1月30日至2021年9月2日进行8周治疗期并设6周安全性随访。
- 纳入每月局灶性起源癫痫发作4次及以上且正在接受稳定治疗(1-3种ASM)的成人患者,在北美和欧洲97个中心入组。
- 患者按2:1:1:2随机接受XEN1101 25、20、10 mg或安慰剂随餐每日一次治疗8周,未进行剂量滴定。
- 325例随机并治疗的患者纳入安全性分析,285例完成8周双盲期;采用改良意向性治疗分析。
主要发现
- 325例患者平均(SD)年龄40.8(13.3)岁,女性168例(51.7%),298例(91.7%)自报种族为白人。
- 每月局灶性起源癫痫频率较基线中位(IQR)降低:25 mg组52.8%(P<.001 vs 安慰剂;IQR,-80.4%至-16.9%)。
- 20 mg组中位降低46.4%(P<.001 vs 安慰剂;IQR,-76.7%至-14.0%)。
- 10 mg组中位降低33.2%(P=.04 vs 安慰剂;IQR,-61.8%至0.0%),安慰剂组降低18.2%(IQR,-37.3%至7.0%)。
- XEN1101总体耐受良好,TEAE与常用ASM相似,未报告导致死亡的TEAE。
关键数值与推荐
- 主要疗效终点为每月局灶性起源癫痫频率较基线的中位百分比变化。
- 25 mg组中位降低52.8%(P<.001 vs 安慰剂),20 mg组降低46.4%(P<.001 vs 安慰剂),10 mg组降低33.2%(P=.04 vs 安慰剂),安慰剂组降低18.2%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Many patients with focal epilepsy experience seizures despite treatment with currently available antiseizure medications (ASMs) and may benefit from novel therapeutics. OBJECTIVE: To evaluate the efficacy and safety of XEN1101, a novel small-molecule selective Kv7.2/Kv7.3 potassium channel opener, in the treatment of focal-onset seizures (FOSs). DESIGN, SETTING, AND PARTICIPANTS: This phase 2b, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging adjunctive trial investigated XEN1101 over an 8-week treatment period from January 30, 2019, to September 2, 2021, and included a 6-week safety follow-up. Adults experiencing 4 or more monthly FOSs while receiving stable treatment (1-3 ASMs) were enrolled at 97 sites in North America and Europe. INTERVENTIONS: Patients were randomized 2:1:1:2 to receive XEN1101, 25, 20, or 10 mg, or placebo with food once daily for 8 weeks. Dosage titration was not used. On completion of the double-blind phase, patients were offered the option of entering an open-label extension (OLE). Patients not participating in the OLE had follow-up safety visits (1 and 6 weeks after the final dose). MAIN OUTCOMES AND MEASURES: The primary efficacy end point was the median percent change from baseline in monthly FOS frequency. Treatment-emergent adverse events (TEAEs) were recorded and comprehensive laboratory assessments were made. Modified intention-to-treat analysis was conducted. RESULTS: A total of 325 patients who were randomized and treated were included in the safety analysis; 285 completed the 8-week double-blind phase. In the 325 patients included, mean (SD) age was 40.8 (13.3) years, 168 (51.7%) were female, and 298 (91.7%) identified their race as White. Treatment with XEN1101 was associated with seizure reduction in a robust dose-response manner. The median (IQR) percent reduction from baseline in monthly FOS frequency was 52.8% (P < .001 vs placebo; IQR, -80.4% to -16.9%) for 25 mg, 46.4% (P < .001 vs placebo; IQR, -76.7% to -14.0%) for 20 mg, and 33.2% (P = .04 vs placebo; IQR, -61.8% to 0.0%) for 10 mg, compared with 18.2% (IQR, -37.3% to 7.0%) for placebo. XEN1101 was generally well tolerated and TEAEs were similar to those of commonly prescribed ASMs, and no TEAEs leading to death were reported. CONCLUSIONS AND RELEVANCE: The efficacy and safety findings of this clinical trial support the further clinical development of XEN1101 for the treatment of FOSs. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03796962.
引用
- French JA, Porter RJ, Perucca E, et al. Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial. JAMA Neurol. 2023. PMID: 37812429. doi:10.1001/jamaneurol.2023.3542
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。